abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 12일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제110회 대한화학회 학술발표회, 총회 및 기기전시회 안내 A 40 year-journey in search of selective antiviral chemotherapy

등록일
2012년 9월 10일 09시 08분 06초
접수번호
1760
발표코드
MEDI-1 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 14시 : 30분
발표형식
분과기조
발표분야
의약화학 - Medicinal Ventures in Korea
저자 및
공동저자
Erik De Clercq
Rega Institute for Medical Research, Belgium, Belgium
My search for a selective antiviral chemotherapy started more than 40 years ago with interferon inducers, then shifted to nucleoside analogs with the discovery of BVDU (brivudin), a highly selective anti-HSV-1 and anti-VZV agent, and to dideoxynucleoside analogs such as d4T (stavudine), as anti-HIV agents. The search culminated in the discovery of acyclic nucleoside phosphonates (ANPs: cidofovir, adefovir, tenofovir) (in collaboration with the late Antonin Hol?), a key class of compounds active against HIV, hepatitis B virus (HBV), and DNA viruses at large; the best known of these compounds is tenofovir, now approved for the treatment of HIV and HBV infections and for the prevention of HIV infections. Along the way, the principle of the non-nucleoside reverse transcriptase inhibitors (NNRTIs) was established. This work, initiated in collaboration with the late Paul A.J. Janssen, eventually led to the identification of rilpivirine as perhaps the "ideal" NNRTI.

상단으로